Payment overview · 2025
General Payments
$240.88
14 reported records · 8 companies
Healthcare provider profile · identity verified
Stacy R Trinkle, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1114982683
Verified facts
What the public records show
CMS Open Payments records show Stacy R Trinkle, M.D. received $240.88 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.65 | 37.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.77 | 20.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.23 | 8.0% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.33 | 7.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.88 | 7.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.68 | 7.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.85 | 6.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.49 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.88 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.99 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.77 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.77 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 493 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 348 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 98 |
| Ezetimibe | Ezetimibe | 267 | 80 |
| Lisinopril | Lisinopril | 260 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 65 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 160 | 39 |
| Omeprazole | Omeprazole | 158 | 43 |
| Montelukast Sodium | Montelukast Sodium | 153 | 45 |
| Losartan Potassium | Losartan Potassium | 151 | 48 |
| Alprazolam | Alprazolam | 150 | 19 |
| Furosemide | Furosemide | 147 | 49 |
| Alendronate Sodium | Alendronate Sodium | 144 | 42 |
| Trazodone Hcl | Trazodone Hcl | 142 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 30 |
| Meloxicam | Meloxicam | 131 | 45 |
| Eliquis | Apixaban | 129 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 121 | 35 |
| Bupropion Xl | Bupropion Hcl | 119 | 35 |
| Gabapentin | Gabapentin | 111 | 28 |
| Metformin Hcl | Metformin Hcl | 109 | 34 |
| Tramadol Hcl | Tramadol Hcl | 108 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 17 |
| Potassium Chloride | Potassium Chloride | 100 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 30 |
| Jardiance | Empagliflozin | 95 | 21 |
| Sertraline Hcl | Sertraline Hcl | 91 | 26 |
| Simvastatin | Simvastatin | 91 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 88 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 19 |
| Glimepiride | Glimepiride | 83 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 24 |
| Metformin Hcl Er | Metformin Hcl | 71 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 20 |
| Ozempic | Semaglutide | 67 | 15 |
| Memantine Hcl | Memantine Hcl | 66 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 17 |
| Pregabalin | Pregabalin | 59 | 12 |
| Synthroid | Levothyroxine Sodium | 56 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 21 |
| Celecoxib | Celecoxib | 52 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Mirtazapine | Mirtazapine | 46 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 13 |
| Naproxen | Naproxen | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 31 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 12 |
| Carvedilol | Carvedilol | 36 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Nexletol | Bempedoic Acid | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Azithromycin | Azithromycin | 15 | 14 |
| Prednisone | Prednisone | 15 | 14 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Tirosint-Sol | Levothyroxine Sodium | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.88 · 14 records | Novo Nordisk Inc | FREESTYLE LIBRE 3, Heplisav-B, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error